EsoCap announced today that the novelty of their unique drug delivery technology has once again been confirmed by a patent, granted by the State of Israel, under number 252893, based on patent application PCT/EP/2015/002601.
So far there is no effective local treatment for diseases of the esophagus due to the ultra-short transit time of convenient drug formulations. This will change with the unique targeted application platform developed by EsoCap together with the University Greifswald, a research partner highly valued and experienced in this field.
